Assuntos
Negro ou Afro-Americano , Doenças Cardiovasculares/etnologia , Doenças Cardiovasculares/epidemiologia , Infecções por Coronavirus/etnologia , Infecções por Coronavirus/mortalidade , Disparidades em Assistência à Saúde , Pneumonia Viral/etnologia , Pneumonia Viral/mortalidade , Negro ou Afro-Americano/estatística & dados numéricos , Betacoronavirus , COVID-19 , Comorbidade , Infecções por Coronavirus/epidemiologia , Efeitos Psicossociais da Doença , Disparidades em Assistência à Saúde/estatística & dados numéricos , Humanos , Expectativa de Vida , Pandemias , Pneumonia Viral/epidemiologia , SARS-CoV-2 , Vigilância de Evento Sentinela , Fatores Socioeconômicos , Estados Unidos/epidemiologiaAssuntos
Doenças Cardiovasculares/etnologia , Doenças Cardiovasculares/terapia , Assistência à Saúde Culturalmente Competente/etnologia , Acessibilidade aos Serviços de Saúde , Disparidades em Assistência à Saúde/etnologia , Grupos Minoritários , Saúde das Minorias/etnologia , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/psicologia , Conhecimentos, Atitudes e Prática em Saúde/etnologia , Disparidades nos Níveis de Saúde , Humanos , Adesão à Medicação/etnologia , Grupos Minoritários/psicologia , Fatores de Risco , Estados Unidos/epidemiologiaRESUMO
PURPOSE OF REVIEW: The purpose of this review is to examine the impact and effectiveness of community interventions for controlling hypertension in African-Americans. The questions addressed are as follows: Which salient prior and current community efforts focus on African-Americans and are most effective in controlling hypertension and patient-related outcomes? How are these efforts implemented and possibly sustained? RECENT FINDINGS: The integration of out-of-office blood pressure measurements, novel hypertension control centers (i.e., barbershops), and community health workers improve hypertension control and may reduce the excess hypertension-related complications in African-Americans. Several community-based interventions may assist effectiveness of clinical care teams, decrease care barriers, and improve adherence. A multifaceted, tailored, multidisciplinary community-based approach may effectively reduce barriers to blood pressure control among African-Americans. Future research should evaluate the long-term benefits of community health workers, barbershops as control centers, and out-of-office blood pressure monitoring upon control and eventually on morbidity and mortality.
Assuntos
Negro ou Afro-Americano , Relações Comunidade-Instituição , Hipertensão/etnologia , Hipertensão/terapia , Pressão Sanguínea/fisiologia , Acessibilidade aos Serviços de Saúde , Disparidades em Assistência à Saúde , Humanos , Hipertensão/fisiopatologiaRESUMO
Medication nonadherence, a major problem in cardiovascular disease (CVD), contributes yearly to approximately 125,000 preventable deaths, which is partly attributable to only about one-half of CVD patients consistently taking prescribed life-saving medications. Current interest has focused on how labeling and education influence adherence. This paper summarizes the scope of CVD nonadherence, describes key U.S. Food and Drug Administration initiatives, and identifies potential targets for improvement. We describe key adherence factors, methods, and technological applications for simplifying regimens and enhancing adherence, and 4 areas where additional collaborative research and implementation involving the regulatory system and clinical community could substantially reduce nonadherence: 1) identifying monitoring methods; 2) improving the evidence base to better understand adherence; 3) developing patient/health provider team-based engagement strategies; and 4) alleviating health disparities. Alignment of U.S. Food and Drug Administration approaches to dissemination of information about appropriate use with clinical practice could improve adherence, and thereby reduce CVD death and disability.
Assuntos
Doenças Cardiovasculares/tratamento farmacológico , Adesão à Medicação , Procedimentos Clínicos , Medicamentos Genéricos , Letramento em Saúde , Promoção da Saúde , Humanos , Disseminação de Informação , Educação de Pacientes como Assunto , Fatores Socioeconômicos , Estados Unidos , United States Food and Drug AdministrationRESUMO
OBJECTIVES: Poorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program. METHODS: Study costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective. RESULTS: Total costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control. CONCLUSIONS: In this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
Assuntos
Determinação da Pressão Arterial/economia , Serviço Hospitalar de Emergência/economia , Cardiopatias/diagnóstico , Cardiopatias/terapia , Hipertensão/diagnóstico , Hipertensão/terapia , Negro ou Afro-Americano , Idoso , Pressão Sanguínea , Análise Custo-Benefício , Feminino , Cardiopatias/etiologia , Humanos , Hipertensão/complicações , Masculino , Pessoa de Meia-Idade , Anos de Vida Ajustados por Qualidade de VidaRESUMO
This article discusses racial/ethnic disparities in hypertension, with particular focus on non-white populations including blacks, Hispanics/Latinos, and Asians. Hypertension and its related morbidity and mortality affect a disproportionate number of black patients compared with white patients. Blacks, Hispanics/Latinos, and Asians have poor rates of hypertension awareness, treatment, and control. Given the high prevalence of comorbidities (e.g., obesity, diabetes, and metabolic syndrome) in these populations, renin-angiotensin-aldosterone system blockers are a good choice for foundation therapy. This review also discusses the importance of adherence and persistence with antihypertensive medication, which remain suboptimal in these non-white populations. Evidence suggests improvement with the use of single-pill combination therapy. Lastly, clinical trial data on the antihypertensive efficacy and safety of the combination of a dihydropyridine calcium channel blocker and an angiotensin receptor blocker, a widely utilized combination, in non-white populations are presented. PubMed was searched using the title/abstract key words (amlodipine AND valsartan AND [hypertension OR hypertensive] AND [black(s) OR African American(s) OR Hispanic(s) OR Latino(s) OR Mexican(s) OR Asian(s)]). In total, eight studies in patients with stage 1 or 2 hypertension were identified (n = 1,111 black, n = 389 Hispanic/Latino, and n = 3,094 Asian). Results showed that treatment with the combination of amlodipine plus valsartan is a reasonable choice for initial therapy or in patients who fail to respond to monotherapy. These drug classes have complementary mechanisms of action and, when used concomitantly, the magnitude of blood pressure lowering in these non-white populations is generally comparable with that seen in non-Hispanic white patients.